A more selective approach to referring women with early-stage breast cancer for costly international laboratory tests can create cost savings of up to 20%, and spare many women from the toxicity of chemotherapy, according to a recent publication from the University of Stellenbosch Business School (USB). – Cape Times (28 October 2021)

The research, conducted by Jaco de Jager as part of his MBA, along with a team of researchers from USB, Stellenbosch University and private practice, found that a one-size-fits-all approach to breast cancer treatment is no longer acceptable in the genomic era. The test is performed centrally in the Netherlands,

with a price tag in euros, making it seemingly unaffordable in the ever-declining South African currency.

Other news